La chaîne d'options affiche les données clés des options sur actions de Tango Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Tango Therapeutics..

Tango Therapeutics (NASDAQ:TNGX) Stock, Chaîne d'Options

TANGO THERAPEUTICS INC

Tango Therapeutics

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Tango Therapeutics Inc

Earnings

Press Releases

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors

Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant  MTAP-deleted Pancreatic or Lung Cancer

News

Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025

Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Financing

Tango Therapeutics Announces $225 Million Financing

TNGX

AnaptysBio

Ardelyx

BridgeBio Oncology Therapeutics, Inc. - Common Stock

BridgeBio Oncology

Bicara Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Immatics

Inventiva S.A. - American Depository Shares

Inventiva

Kodiak Sciences

Kura Oncology

MiMedx Group

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Nurix Therapeutics

Oric Pharmaceuticals, Inc. - Common Stock

ORIC Pharmaceuticals

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Prime Medicine

Relay Therapeutics

Rezolute

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Upstream Bio

UroGen Pharma

Xencor

Guggenheim

Piper Sandler

HC Wainwright & Co.

B. Riley Securities

Comments

Tango Therapeutics

Tango Therapeutics (TNGX) Options

Tango Therapeutics (NASDAQ:TNGX) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL